HomeCompareENCUF vs PFE

ENCUF vs PFE: Dividend Comparison 2026

ENCUF yields 72.73% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENCUF wins by $1.14M in total portfolio value
10 years
ENCUF
ENCUF
● Live price
72.73%
Share price
$2.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.19M
Annual income
$322,041.74
Full ENCUF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ENCUF vs PFE

📍 ENCUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENCUFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENCUF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENCUF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENCUF
Annual income on $10K today (after 15% tax)
$6,181.82/yr
After 10yr DRIP, annual income (after tax)
$273,735.48/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ENCUF beats the other by $251,415.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENCUF + PFE for your $10,000?

ENCUF: 50%PFE: 50%
100% PFE50/50100% ENCUF
Portfolio after 10yr
$621.3K
Annual income
$174,150.23/yr
Blended yield
28.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ENCUF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENCUF buys
0
PFE buys
0
No recent congressional trades found for ENCUF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENCUFPFE
Forward yield72.73%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.19M$49.6K
Annual income after 10y$322,041.74$26,258.71
Total dividends collected$1.02M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENCUF vs PFE ($10,000, DRIP)

YearENCUF PortfolioENCUF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$17,973$7,272.73$9,153$693.39+$8.8KENCUF
2$31,447$12,215.96$8,593$849.25+$22.9KENCUF
3$53,624$19,975.88$8,336$1,066.78+$45.3KENCUF
4$89,213$31,834.98$8,437$1,384.80+$80.8KENCUF
5$144,956$49,498.07$9,013$1,875.40+$135.9KENCUF
6$230,267$75,164.58$10,306$2,680.72+$220.0KENCUF
7$357,976$111,590.27$12,820$4,101.38+$345.2KENCUF
8$545,165$162,130.50$17,673$6,826.70+$527.5KENCUF
9$814,083$230,757.00$27,543$12,591.86+$786.5KENCUF
10$1,193,111$322,041.74$49,560$26,258.71+$1.14MENCUF

ENCUF vs PFE: Complete Analysis 2026

ENCUFStock

enCore Energy Corp. engages in the acquisition and exploration of resource properties in the United States. It holds a 100% interest in Crownpoint and Hosta Butte uranium project area covers 3,020 acres located in the Grants Uranium Belt, New Mexico. The company also holds interest in the Marquez-Juan Tafoya property consists of private mineral leases totaling 18,596 acres located in McKinley and Sandoval counties of New Mexico; the Nose Rock project comprising 42 owned unpatented lode mining claims comprising approximately 800 acres located in McKinley County, New Mexico; and the Moonshine Springs project comprises approximately 1000 acres, including 23 owned unpatented lode mining claims, 7 unpatented lode mining claims, and 320 acres of fee land under lease located in Mohave County, Arizona. In addition, it holds interest in the White Canyon District and Utah property package, including the Geitus, Blue Jay, Marcy Look, and Cedar Mountain projects located to the northwest of the White Mesa Mill at Blanding County, Utah. Further, the company holds a 100% interest in Dewey Burdock project comprises approximately 12,613 surface acres and 16,962 net mineral acres located in South Dakota; Gas Hills project consists of approximately 1,280 surface acres and 12,960 net mineral acres of unpatented lode mining claims located in Wyoming; and West Largo project consist of approximately 3,840 acres located in McKinley County, New Mexico. Additionally, it holds a 100% interest in Ambrosia Lake - Treeline property consists of deeded mineral rights totaling 24,555 acres and unpatented mining claims covering approximately 1,700 acres; and Checkerboard mineral rights covering a land position of approximately 300,000 acres located in the Grants Uranium District. The company was formerly known as Wolfpack Gold Corp. and changed its name to enCore Energy Corp. in August 2014. enCore Energy Corp. was incorporated in 2009 and is headquartered in Corpus Christi, Texas.

Full ENCUF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ENCUF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENCUF vs SCHDENCUF vs JEPIENCUF vs OENCUF vs KOENCUF vs MAINENCUF vs JNJENCUF vs MRKENCUF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.